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Genetic-based susceptibility to bilirubin neurotoxicity and chronic bilirubin
encephalopathy (kernicterus) is still poorly understood. Neonatal jaundice affects
60–80% of newborns, and considerable effort goes into preventing this relatively benign
condition from escalating into the development of kernicterus making the incidence
of this potentially devastating condition very rare in more developed countries. The
current understanding of the genetic background of kernicterus is largely comprised of
mutations related to alterations of bilirubin production, elimination, or both. Less is known
about mutations that may predispose or protect against CNS bilirubin neurotoxicity.
The lack of a monogenetic source for this risk of bilirubin neurotoxicity suggests that
disease progression is dependent upon an overall decrease in the functionality of one
or more essential genetically controlled metabolic pathways. In other words, a “load”
is placed on key pathways in the form of multiple genetic variants that combine to
create a vulnerable phenotype. The idea of epistatic interactions creating a pathway
genetic load (PGL) that affects the response to a specific insult has been previously
reported as a PGL score. We hypothesize that the PGL score can be used to investigate
whether increased susceptibility to bilirubin-induced CNS damage in neonates is due
to a mutational load being placed on key genetic pathways important to the central
nervous system’s response to bilirubin neurotoxicity. We propose a modification of the
PGL score method that replaces the use of a canonical pathway with custom gene
lists organized into three tiers with descending levels of evidence combined with the
utilization of single nucleotide polymorphism (SNP) causality prediction methods. The
PGL score has the potential to explain the genetic background of complex bilirubin
induced neurological disorders (BIND) such as kernicterus and could be the key to
understanding ranges of outcome severity in complex diseases. We anticipate that this
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method could be useful for improving the care of jaundiced newborns through its use
as an at-risk screen. Importantly, this method would also be useful in uncovering basic
knowledge about this and other polygenetic diseases whose genetic source is difficult
to discern through traditional means such as a genome-wide association study.
Keywords: bilirubin, kernicterus, pathway genetic load score, bilirubin encephalopathy, GWAS
INTRODUCTION
Chronic bilirubin encephalopathy (CBE—also known as
kernicterus) is caused by exposure to toxic levels of unconjugated
bilirubin (UCB) in severely jaundiced newborns resulting in
deposition of bilirubin in the brain (Shapiro, 2010). Neonatal
jaundice, present in 60–80% of newborns, is commonly due
to unconjugated hyperbilirubinemia and is assessed clinically
by measuring total serum bilirubin (TSB) and UCB. Effective
monitoring and treatment has helped make the development
of CBE a rare event in the majority of countries despite
the prevalence of neonatal jaundice. The concentration of
albumin, the major binding protein of bilirubin in the blood,
and its ability to bind bilirubin are important factors in the
transport of bilirubin to the liver for clearance. To prevent
excessive hyperbilirubinemia infants are commonly treated
with phototherapy to convert bilirubin into water-soluble
photoisomers that can be excreted by the liver and kidneys.When
hyperbilirubinemia exceeds a specific level defined in clinical
guidelines (e.g., American Academy of Pediatrics Subcommittee
on Hyperbilirubinemia, 2004) exchange transfusions may be
performed. While these treatments have significantly decreased
the overall incidence of CBE in most industrialized countries,
CBE with lifelong neurological sequelae still occurs, and is a
major problem in many areas of the world, especially in low-
and middle-income countries (Olusanya et al., 2014; Greco et al.,
2016).
Despite the widespread use of TSB levels as a guide for
intervention in jaundiced newborns, TSB alone has been shown
repeatedly to be a poor predictor of neurological impairment
(Ahlfors et al., 2009; Gamaleldin et al., 2011). TSB measures
bilirubin levels in blood, where more than 99% of bilirubin is
bound to proteins, especially albumin (90% or more) (Hulzebos
and Dijk, 2014), but does not measure bilirubin in brain
tissue. The toxic form of bilirubin, i.e., free, unbound bilirubin
(Bf) correlates better with both acute and chronic bilirubin
encephalopathy (Nakamura et al., 1985; Wennberg et al., 2006;
Ahlfors et al., 2009; Amin et al., 2016). The inability to easily
and reliably measure Bf levels, in addition to the complex nature
of unbound bilirubin deposition and toxicity, has impaired
investigations of predictive accuracy of Bf for CBE. Furthermore,
subtle chronic bilirubin encephalopathy, part of a spectrum
of kernicterus or bilirubin-induced neurological dysfunction
(BIND) (Shapiro, 2005, 2010; Bhutani and Johnson-Hamerman,
2015), has been difficult to link retrospectively to TSB and UCB
levels.
We hypothesize that the production, transport, and
elimination of bilirubin, as well as the cellular response to
bilirubin, have an important genetic component. If this genetic
component could be better understood, it would enhance
identification of patients at risk and allow for an individualized
therapeutic approach to hyperbilirubinemia. In this paper,
we first review genetic methods commonly used to study
poly-genetic diseases in large populations and show that these
methods cannot be used in a disease such as kernicterus. We
then propose a modified use of the pathway genetic load (PGL)
score method to decipher the genetic factors that contribute to
increased susceptibility to bilirubin neurotoxicity. Finally, we
summarize our proposal and describe the current status of this
ongoing project.
THE PROMISE OF GENETICS
Genetic Analysis and Disease
The study of molecular genetics has identified more than
6000 different monogenetic diseases, mostly through familial
linkage analysis. Autosomal dominant, autosomal recessive,
and X-linked genetic diseases with complete penetrance were
the first and easiest to identify by linkage analysis. Later,
genome-wide association studies (GWAS) were developed to
identify genes contributing to incompletely penetrant and poly-
genetic diseases. Both methods have successfully identified key
genetic contributors to various diseases. However, these genetic
analyses have also had many failures. Studies of thousands of
individuals have failed to uncover significant genetic heritability
for numerous diseases (the “missing heritability” problem),
leading to a re-evaluation of the basic tenants of GWAS (reviewed
in Marjoram et al., 2014).
Current Strategies: Successes and
Shortcomings
Family linkage analysis is very good at identifying rare mutations
with large effects that confer susceptibility to common diseases.
Examples include the BRCA1 and BRCA2 genes in breast
cancer (Easton et al., 1995; Ford et al., 1998). By comparison,
GWAS studies excel at analyzing complex diseases and disease
genes with a weak effect (Risch and Merikangas, 1996). The
most common target in GWAS studies has been the single
nucleotide polymorphism (SNP) (Palmer and Cardon, 2005).
SNPs identified in GWAS studies have largely been shown to
be representative of loci of interest and thus have an indirect
association with the actual causal variant(s). For example, the
FTO gene has been shown through GWAS studies to associate
with obesity. However, its effect on obesity was eventually shown
to be through an enhancer mechanism on downstream genes,
including IRX3 and IRX5 (Smemo et al., 2014; Claussnitzer
et al., 2015). A major advantage of GWAS studies is the
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unbiased inclusion of the entire genome, thus allowing for the
identification of novel loci of interest and the development of
original hypotheses to be tested. Once statistically significant
associations have been established with one or more loci, they
can be confirmed with data from other GWAS populations or
through determination of the causal relationship by experimental
means (Sekar et al., 2016).
While GWAS studies have produced important discoveries,
their experimental designs impose hurdles that can present
significant challenges. The first hurdle is population size. GWAS
studies are, by definition, very large, requiring scans of large
numbers of SNPs. In order to reach statistical significance, sample
sizes in the thousands are required. For common diseases, very
large sample sizes are attainable; however, for rarer diseases,
sample size becomes problematic and is prohibitive in some
cases. The second hurdle is that GWAS studies focus on
identifying one or sometimes a small group of mutations in
loci that are associated with a disease phenotype. It is then
left to interpretation what, if any, relationship there is between
these loci and the condition being studied. The third hurdle
is that GWAS studies largely operate on the common disease–
common variant hypothesis. This hypothesis states that the
genetic contributions to the susceptibility of common diseases are
attributable to a small number of variants present in more than
1–5% of the population (Manolio, 2010). While this hypothesis
has proven useful for common diseases, it is not as applicable to
rare diseases and more complex diseases whose mutations may
not reach the 1% threshold. The fourth and final hurdle is that
GWAS is not well suited to diseases in which the genetic impact
on a disease state is largely dependent upon epistatic interactions.
Epistatic interactions are described as the interaction between
two loci whereby the phenotype of one locus depends on the
genotype of the second locus (Carlborg and Haley, 2004). For
quantitative traits, epistasis describes a situation where the sum
of the single locus effects cannot be used to predict the phenotype
of a particular genotype (Carlborg and Haley, 2004). When
considering the effect of genetic interaction at the pathway level,
one or two small effect mutations may not cause a noticeable
phenotype, but 10 or 20 mutations could combine to create a
significant “load” on the pathway and cause deterioration in
functionality, leading to a diseased state. Epistatic interactions
could also occur within a single gene where one SNP functionally
affects another. In this model, neither mutation alone causes an
effect, but together they combine to act synergistically to cause an
effect greater than would be predicted by an additive model.
AN ALTERNATIVE APPROACH: THE
PATHWAY GENETIC LOAD (PGL) SCORE
Description of the Pathway Genetic Load
Score
The GWAS method has identified a number of genetic
associations that are important to numerous complex diseases.
Within these predictions, often a large portion of the heritability
remains to be uncovered. Understanding this “missing
heritability” has become one of the major goals of clinical
genetic research. Some of the tactics that have been proposed
include combining linkage and association analysis (Ott et al.,
2011), correcting an overestimation in heritability (Zuk et al.,
2012), and considering gene–gene interactions (Liu et al., 2012).
A particularly intriguing approach to resolving the missing
heritability problem was recently presented by Huebinger et al.,
who used a PGL risk score (Huebinger et al., 2010) to predict
the outcome of patients exposed to severe burn trauma. The PGL
risk score was defined as the “sum total of mutant alleles present
at risk loci within a common biological pathway.” The PGL risk
score is calculated using a number of assumptions that require
certain concessions to be made in order to be both useful and
accurate. Others have used similar pathway analysis methods to
study genetic risks for coronary infarction (Yiannakouris et al.,
2006; Trichopoulou et al., 2008) and Parkinson’s disease (Lesnick
et al., 2007). The PGL method has the potential to offer an
alternative method to GWAS for identifying relevant genetic
contributors, especially for lower incidence diseases.
APPLYING THE PGL RISK SCORE TO
BILIRUBIN ENCEPHALOPATHY
Description of Bilirubin Encephalopathy
Kernicterus or CBE is a rare disease in aﬄuent countries
because of preventive measures. However, neonatal jaundice is
very common, occurring in 60–80% of full term (≥37 weeks’
gestational age) otherwise healthy newborns. About 7% of
jaundiced infants receive phototherapy (Bhutani et al., 2004a,b,
2013; Keren et al., 2009). Classical kernicterus is a well-described
clinical tetrad of (i) abnormal motor control, movements, and
muscle tone, (ii) an auditory processing disturbance with or
without hearing loss, (iii) oculomotor impairments, especially
impairment of upward vertical gaze, and (iv) dysplasia of the
enamel of deciduous (baby) teeth, an abnormality leading to
pitting, flaking, and chipping of the enamel (Shapiro et al., 2006).
In addition to classical kernicterus, subclasses of kernicterus are
characterized as auditory predominant, motor predominant, and
subtle kernicterus (BIND) (Shapiro, 2010).
While efforts to prevent dangerous hyperbilirubinemia have
been successful in the developed world, a high incidence
of glucose-6-phosphate dehydrogenase deficiency, delays in
seeking care, lack of TSB screening resources, and ineffective
treatments in low and middle income countries ensure that
bilirubin encephalopathy remains a serious world health problem
(Olusanya et al., 2014; Slusher et al., 2015). Ogunlesi et al. (2007)
reported a 2.7% incidence of bilirubin encephalopathy among
neonates admitted to two hospitals in Nigeria between 2002
and 2005. This high prevalence of kernicterus, in conjunction
with new reports of the more subtle predominantly auditory
and predominantly motor forms of kernicterus (Shapiro and
Popelka, 2011), underscores the need to better understand
why hyperbilirubinemia causes permanent brain damage in
some infants and not in others. The relative rarity of
kernicterus in the West and, to a lesser extent, milder forms
of bilirubin encephalopathy, makes it exceedingly difficult to
perform traditional genetic analysis through large population
GWAS studies. In addition, the apparent wide range of
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susceptibility to a common bilirubin exposure points toward
polygenetic determination of risk for neurotoxicity. The current
understanding of the genetics of bilirubin encephalopathy
(described below) also points toward a polygenetic cause for
increased risks to bilirubin neurotoxicity.
Together, these factors indicate a need for an alternative
method, such as the PGL risk score, to understand genetic
factors contributing to risk for CBE. The PGL method is
a good fit for bilirubin encephalopathy because bilirubin
encephalopathy results from a one-time insult, similar to the
severe burns examined in Huebinger et al.’s study. For bilirubin
encephalopathy that insult is in the form of moderate to extreme
hyperbilirubinemia at birth. Also, similar to the total body surface
area measure for a serious burn, the body’s response to bilirubin
toxicity is variable and not well explained by its key diagnostic
test, peak TSB levels.
While significant progress has been made in understanding
the various causes of neonatal hyperbilirubinemia, few studies
have been undertaken to understand the mechanism of
bilirubin toxicity. Multiple cellular and molecular cascades likely
underlie bilirubin-induced neuronal injury, including plasma
membrane perturbations, excitotoxicity, neuroinflammation,
oxidative stress, and cell cycle arrest. It is likely that variable
effectiveness of the cellular response to bilirubin exposure
contributes to the range of observed clinical outcomes. To
explain part of this variability, we hypothesize that a combination
of SNPs in key pathways are responsible for creating a
vulnerable state to bilirubin neurotoxicity. The development of
this vulnerable state likely occurs through a combination of
increased CNS bilirubin levels and impaired cellular response to
bilirubin.
On the basis of the current understanding of bilirubin
encephalopathy, we suspect that the genetic impact is the result of
the combined effect of mutations with relatively small effects that,
if present alone, would otherwise be clinically benign. Alternative
hypotheses that could also explain the TSB’s poor predictive value
for kernicterus include disrupted albumin/bilirubin binding
capacity, reductions in available albumin, and use of TSB levels
as the sole diagnostic test for bilirubin exposure. A number of
studies have been published that examine the issue of TSB’s
reliability in both predicting and improving outcomes. These
studies have compared the effectiveness of alternatives to TSB
such as albumin/bilirubin binding capacity (Kapitulnik et al.,
1974), unbound (free) bilirubin levels (Cashore and Oh, 1982;
Ahlfors et al., 2009; Morioka et al., 2015), and bilirubin-albumin
ratios either in place of or in addition to TSB testing (Ahlfors,
1994; Amin et al., 2001, 2016).
While Nakamura et al. showed over 30 years ago that free
bilirubin levels predict neurotoxicity better than TSB levels do
(Nakamura et al., 1985), technical issues, reliability, and lack of
availability of these tests have called their usefulness into question
(McDonagh and Maisels, 2006; Hulzebos and Dijk, 2014). The
use of the bilirubin/albumin ratio has also been shown to be as
strong a predictor of neurotoxicity as TSB (Iskander et al., 2014)
but has not been shown to offer an advantage in predicting or
improving outcomes over TSB alone (Iskander et al., 2014) or
when used in addition to TSB (Hulzebos et al., 2014).
Known Genetics of Bilirubin
Encephalopathy
Bilirubin is largely a breakdown product of hemoglobin. Bilirubin
rises after birth in all mammals, and in humans usually peaks at
3–5 days after birth and then falls to very low values through the
rest of life (Kivlahan and James, 1984; Maisels et al., 2014). It is
bound in the blood to proteins, especially albumin. Very little
bilirubin normally reaches brain tissue. There is evidence that at
low levels bilirubin is beneficial, acting as a natural antioxidant
(Adin et al., 2005; Bakrania et al., 2016), but very high levels can
exceed the buffering capacity of the blood and allow bilirubin
to move into the brain, causing a unique pattern of brain injury
(Shapiro et al., 2006; Shapiro, 2010).
Hyperbilirubinemia results from the excessive breakdown of
red blood cells (RBC) (hemolysis) or impaired elimination
of bilirubin. Most genetic abnormalities linked to the
presentation of bilirubin encephalopathy are related to
production and elimination. Hemolysis may occur as a
result of immune mechanisms (e.g., Rh disease, ABO blood
group incompatibilities), increased fragility of RBC [Glucose-6-
phosphate dehydrogenase (G6PD) deficiency], or from bleeding
(e.g., cephalohematoma). Decreased elimination is enhanced in
infants with genetic variations in the enzyme or the promotor
regions of UDP-glucuronosyltransferase 1A1 (UGT1A1),
(Watchko and Tiribelli, 2013). Other factors that contribute to
hyperbilirubinemia include decreased oral intake and stooling.
It is believed that hyperbilirubinemia due to decreased oral
intake may account for a substantial number of readmissions
of newborns to hospitals after discharge (Seidman et al., 1995;
Farhat and Rajab, 2011; Maisels et al., 2014).
Outcome Variability at the Same or Very
Similar TSB Levels
Possible sources of outcome variability include factors such as the
source of hyperbilirubinemia, the gestational age of the infant,
the duration of exposure, the kinetics of bilirubin’s movement
between miscible compartments of the body (e.g., blood, tissue,
CNS, extracellular, and intracellular), the type of treatment
administered and other known risk factors such as acidosis or
sepsis (Shapiro, 2010; Hulzebos and Dijk, 2014). Furthermore,
a significant genetic contribution to the susceptibility of an
individual to neurological damage due to hyperbilirubinemia
may be related to the disruption of mitochondria, which may
in turn affect cellular and molecular cascades including plasma
membrane perturbations, excitotoxicity, neuroinflammation,
oxidative stress, and cell cycle arrest referred to previously
(Rodrigues et al., 2002a,b; Vaz et al., 2010; Brites, 2011; Barateiro
et al., 2012).
Clinical observations have shown that in cases where TSB
reaches extremely high levels (>40mg/dL or >680µM1), the
likelihood of developing at least some form of kernicterus
approaches 100%, although exceptions to this generalization
have been published (Newman et al., 2003, 2006). These clinical
observations likely indicate that for most neonates, there is a
1Conversion from international units of bilirubin (µM) to mg/dL (a.k.a. mg%) is
17.1, i.e., 1mg/dL= 17.1µM.
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maximum level of bilirubin or “tipping point” where the body’s
natural defense mechanisms for clearing unbound bilirubin from
susceptible neurons are overwhelmed and deposition occurs.
However, because kernicterus has been known to develop at
lower TSB levels, it is clear that the maximum level of bilirubin
exposure varies from person to person (Ritter et al., 1982;
Odutolu and Emmerson, 2013). Even allowing for external
factors and the inexact nature of TSB as a measure of exposure
to bilirubin in brain tissue, there is still a strong likelihood that
genetic variability contributes to the overall susceptibility of a
child to bilirubin neurotoxicity and subsequent chronic adverse
neurodevelopmental sequelae.
Selecting a “Pathway” for Bilirubin
Encephalopathy
Here we propose using the PGL method in order to determine
the extent to which a multifactorial genetic response contributes
to the variable susceptibility to bilirubin toxicity and the resultant
variability in disease outcome. Due to the lack of a CBE GWAS to
guide our pathway selection, we propose creating three custom
“pathways” of genes that are organized into “tiers” based on
the mechanism of physiological contributions and the relative
strength of evidence that these genes contribute to bilirubin
susceptibility and sensitivity. Each of these three gene tiers will be
analyzed individually and independently using the PGL method.
The PGL method differs from traditional association analysis
in a number of important ways. First, the PGL score uses a
biased approach by leveraging what is already known about
a disease to focus on a specific set of genes (pathway) and
SNPs. Second, unlike GWAS and linkage analysis, the PGL
score method involves the calculation of a risk score. Third, the
method can be performed using a smaller sample size than in
GWAS studies because the number of variables is dependent
on candidate pathway size, thus reducing the required sample
size to achieve adequate statistical power. Finally, the PGL
method allows detection of combinatorial epistatic interactions
that would otherwise have been missed by both GWAS and
linkage analysis.
The decision to use a biased approach comes with the
understanding that the available knowledge will very likely
present only a partial picture of the entire genetic heritability.
However, the hope is that if enough of the biological background
is known, then the analysis will prove to be useful and actionable.
By accepting a higher rate of false negatives, we will find it is
then possible to drastically reduce the number of genes and thus
variants being surveyed. Reducing the number of SNPs being
investigated allows for a corresponding reduction in sample
size, opening up analysis to rarer diseases. Huebinger et al.
used their knowledge of injury and infection to select the Toll-
like receptor signaling pathway to assess whether an increased
PGL risk score within this pathway could predict the outcome
following burn trauma (Huebinger et al., 2010). Similarly, using
the PGL method, we will perform a targeted genetic analysis on a
small number of samples and will determine whether a common
mutational “load” exists in our affected individuals that points
toward the development of a state of bilirubin hypersensitivity.
Tier 1: Known Genetic Risk Factors for Increased
Hyperbilirubinemia: Genes for Increased Production
or Decreased Elimination of Bilirubin
The tier 1 “pathway” is composed of genes known as contributing
risk factors for hyperbilirubinemia and bilirubin encephalopathy
(i.e., classically recognized) (Watchko and Lin, 2010, 2012;
Watchko, 2013). This pathway includes all of the known
mechanisms contributing to the production and elimination of
bilirubin.
The production pathway includes genes that predispose
to hemolysis or reduce RBC lifespan, leading to increased
bilirubin production in neonates. G6PD and Pyruvate Kinase
(PK) mutations can cause defects in RBC metabolism (Watchko
and Lin, 2012). Several conditions lead to reduced RBC lifespan
such as hereditary spherocytosis, elliptocytosis, stomatocytosis,
and infantile pyknocytosis (Delaunay, 2007; Kraus et al., 2010;
Kaplan et al., 2014).
Genes that affect elimination of bilirubin include allelic
variation in the regulatory region of the UGT1A1 gene (affecting
bilirubin conjugation in the liver, Gilbert’s syndrome) and the
solute transporter SLCO1B1 that facilitates UCB uptake and
influences the ability to clear bilirubin. Poorly functioning
variants of either gene can contribute to hyperbilirubinemia
(Johnson et al., 2009; Watchko and Lin, 2010). We consider these
genes to be the first tier of primary candidate genes that are
known to influence bilirubin levels. It is reasonable to presume
that a combination of subtle, seemingly benignmutations in these
genes could result in increasing bilirubin to toxic levels. The
complete tier 1 list can be seen in (Supplemental Table 1).
Tier 2: In vitro—Genetic Responses to Bilirubin in
Neuronal and Glial Cell Cultures
The tier 2 “pathway” is composed of genes identified in recent
studies as genes whose expression levels are modulated by
bilirubin exposure. These genes were identified by in vitro
experiments in human SH-SY5Y neuroblastoma cells (Calligaris
et al., 2009). In these experiments, the cells were exposed to
UCB for 24 h and transcriptome changes were examined by
high-density oligonucleotide microarrays. Selected genes were
then validated by RT-PCR. These genes represent neuronal genes
that had altered expression in response to bilirubin exposure.
In addition, we have also included those genes that are related
to the immunoreactive response shown to occur in primary
rodent neuronal and glial cultures exposed to UCB (Brites, 2012).
Primary glial cell lines including rat astrocytes (Fernandes et al.,
2004, 2006, 2007b) rat microglia (Gordo et al., 2006; Silva et al.,
2010), and rat oligodendrocytes (Barateiro et al., 2012, 2013,
2014) have been shown to be sensitive to exposure of UCB leading
to cell death in all cases. In addition, rat astrocytes and microglia,
but not oligodendrocytes release pro-inflammatory cytokines
upon exposure to UCB (Gordo et al., 2006; Fernandes et al.,
2007a; Barateiro et al., 2012). It is thought that this inflammatory
response is a crucial element in the UCB response and plays
a major role in the cell death (Vaz et al., 2011; Silva et al.,
2012). Unlike the list of genes in tier 1, this list represents a
response to bilirubin exposure rather than the production of a
hyperbilirubinemic state. We hypothesize that this list contains a
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core network of genes that are important at the cellular level to
respond to toxic levels of bilirubin. The complete tier 2 list can be
seen in Supplemental Table 2.
Tier 3: In silico—Genes Identified by Bioinformatics
Analysis
We hypothesize that gene expression differences in susceptible
vs. resistant regions of the brain may provide some insight
into additional secondary mediators of bilirubin neurotoxicity.
The tier 3 “pathway” is composed of genes identified to be
differentially expressed in regions of the brain that are susceptible
to bilirubin compared to similar regions in close proximity that
are resistant. We chose two pairs of susceptible vs. resistant
brain regions for comparison based on clinical knowledge
(Shapiro, 2005, 2010) and animal studies (Gazzin et al., 2012):
(1) the inferior colliculus (IC) is susceptible to bilirubin toxicity
compared to, superior colliculus (SC), the resistant control, and
(2) the globus pallidus (GP) vs. putamen (PU). The IC is in part
responsible for the auditory abnormalities and the GP for the
motor abnormalities in kernicterus and BIND. Furthermore, in
addition to showing a marked difference in response to bilirubin
toxicity, these regions of the brain are in close proximity to each
other, thus minimizing the potential for variability in blood flow
and other factors.
The Allen Brain Atlas is a collection of freely available
online resources integrating extensive gene expression and
neuroanatomical data from developing and adult human brains
(Website: © 2015 Allen Institute for Brain Science. Allen Human
Brain Atlas [Internet]. Available from: http://human.brain-map.
org) (Hawrylycz et al., 2012). The atlas allows exploration of
the expression of known genes in carefully defined anatomical
regions of the human brain at high resolution. We used the
brain atlas to compare gene expression between regions that are
susceptible to bilirubin toxicity and those that are resistant.
For the creation of Tier 3 A and B we identified those genes
whose expression was significantly different (p < 0.05) between
the IC (susceptible) compared to SC (resistant) brain regions in
normal adult brains using the resources of the Allen Brain Atlas.
From these genes we selected 100 genes with the largest increase
in expression level in the IC vs. SC (3A) and 100 genes with
the largest increase in expression level in the SC vs. IC (3B), as
measured by fold change, for a total of 200 genes. For the creation
of Tier 3 C and D we identified those genes whose expression was
significantly different (p < 0.05) between GP (susceptible) and
PU (resistant) brain regions. And as with 3A and 3B we selected
100 genes with the largest increase in expression level in the GP
vs. PU, (3C) and 100 genes with the largest increase in expression
level in the PU vs. GP (3D), as measured by fold change, for a
total of 200 genes.
We chose to limit our gene lists to 200 genes per comparison
because we believe that this strategy provides a fair representation
of those genes that show the most dramatic change between
regions and thus potentially reflect the genetic components
underlying the physiological differences that contribute to region
specific bilirubin toxicity resistance or susceptibility. While we
recognize that this strategy will not encompass all the genes
responsible for the varied response to bilirubin we believe that
this abbreviated strategy will allow for the identification of
major contributors and their associated pathways thus opening
up new avenues for future research. We hypothesize that
analyzing the expression of the genes in these differentially
affected regions of the brain will reveal susceptible and protected
genetic profiles within the brain that could then be extrapolated
to better understand the variable susceptibility of individuals
to bilirubin toxicity. The complete tier 3 list can be seen in
Supplemental Table 3.
Selecting Key SNPs for PGL Risk Score
Calculation and Analysis
After the pathway of interest is selected, the next step is to
select the candidate SNPs from within the pathway. For this
crucial step, Huebinger et al. chose to create their candidate
SNP list from variants that had previously published associations
with burn trauma. Once these SNPs are determined, the PGL
risk score can be calculated by summing the numerical scores
for genotypes across all SNPs that are homozygous protective
(assigned a score of “0”), heterozygous (score of “1”) and
homozygous detrimental (score of “2”). The initial calculation
results in the raw risk score where each SNP is treated equally.
The risk score is then weighted to better represent the impact
of each of the SNPs. For this step Huebinger et al. chose to
use the adjusted odds ratio from previously reported studies
for each SNP between each individual locus and either death
or sepsis. For loci without previously published data, the value
was left unweighted. The data could then be analyzed further
by Mann-Whitney U Test to investigate whether the PGL risk
score alone can predict developing sepsis. In addition, the
multivariate logistic regression test could be used to investigate
the simultaneous effect of multiple variables as risk factors for
various outcomes. A synopsis of the PGL workflow can be seen
in Figure 1.
For their analysis Huebinger et al. chose to adjust for age,
gender, race, total body surface area burned, and inhalation
injury. They were able to show that each unit increase in weighted
PGL risk scores was associated with increased probability of both
complicated sepsis and death. By analyzing data from only 155
burn trauma patients and using only 6 SNPs at 6 different loci,
they showed that a larger PGL risk score indicated increased
odds of both sepsis and mortality in response to burn trauma.
This work, along with other similar pathway load work (Lesnick
et al., 2007), demonstrates that by using a targeted approach
it is possible to show that a genetic load placed on a crucial
pathway can have predictive capabilities even with a relatively
small sample size.
To develop a SNP set for each tier, we will collect whole
exome sequence data from patients with moderate to high TSB
levels (10–25mg/dL and >25mg/dL respectively) both with
and without evidence of classic auditory or motor dysfunction.
We will identify positive “hits” through a pipeline utilizing
the Partek Genomics Suite and Flow (Partek Inc., St. Louis,
MO, USA). Causal variants in this study will then be identified
through the use of QIAGEN’s Ingenuity R© Variant AnalysisTM
software (www.qiagen.com/ingenuity) from QIAGEN Redwood
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FIGURE 1 | Pathway genetic load risk score workflow. Workflow for
developing and testing a PGL risk score according to Huebinger et al. (2010).
The raw and weighted scores are analyzed separately to assess the impact of
relevant disease association data on the PGL risk score calculation.
Abbreviations: SNP, Single Nucleotide Polymorphism; PGL, Pathway Genetic
Load; aOR, adjusted odds ratio gathered from a relevant GWAS study.
City. Ingenuity R© Variant AnalysisTM allows for multiple types of
SNP filtering to create a list of screened causal variants that are
present in a significant number of the case group vs. controls. The
causal variant filter is based on the American College of Medical
Genetics and Genomics (ACMG) categorization guidelines
(Richards et al., 2015). Alternatively, or in combination with
ACMG categorization, it is possible to select variants that cause
a gain of function or a loss of function based on information
in the Ingenuity R© Knowledge Base. The Ingenuity R© Knowledge
Base is a “repository of expertly curated biological interactions
and functional annotations created from millions of individually
modeled relationships between proteins, genes, complexes,
cells, tissues, drugs, and diseases” manually created from the
literature (http://www.ingenuity.com/science/knowledge-base).
The causal variant list can also be filtered to include only those
genes present in each of the gene set tiers.
Once the key SNPs predicted to be deleterious are identified,
the PGL risk score can be calculated. The raw score will be
calculated from the individual genotypes as described above as
homozygous protective = 0, heterozygous = 1 and compound
heterozygote/homozygous deleterious = 2. The raw score will
then be summed and the adjusted odds ratio, confidence interval,
and p-value will be calculated. Multivariate logistic regression
will then be used to evaluate the simultaneous effects of
multiple variables as risk factors for the development of one
of three outcomes. Possible outcomes include predominantly
auditory dysfunction, predominantly motor dysfunction, and
auditory plus motor dysfunction (classic kernicterus) (Shapiro,
2010). Outcomes will be further analyzed with adjustments
for TSB, albumin, gender, race, sepsis, and gestational age at
birth.
For weighted analysis, the SNPs will be weighted based on
the Sorting Intolerant from Tolerant (SIFT) score (Ng, 2003) or
the Combined Annotation-Dependent Deletion (CADD) score
(Kircher et al., 2014). By utilizing the ACMG score for initial
selection and the SIFT or CADD scores for weighting, we are
able to evaluate the direct effect of a SNP, a crucial difference
from the GWAS based method. A synopsis of the proposed PGL
workflow to be used for bilirubin encephalopathy can be seen in
Figure 2.
SHORTCOMINGS OF THE PATHWAY
GENETIC LOAD SCORE
While the PGL method presented has been successful at
producing significant and meaningful results, there are
drawbacks to using PGL risk score analysis. These drawbacks
include the previously described risk for false negatives, the
possibility that major contributing factors are outside the
pathway chosen to be studied, and that considerable cross-talk is
occurring between overlapping pathways, leading to confusing
and difficult to confirm results. In addition, the selections of the
target pathway and the set of SNPs are based on the information
available at the time of the study which may not be complete
enough to make accurate selections. To address this issue, we
have used three different methods to develop our tiers aimed
at maximizing the currently available knowledge base for CBE.
Finally, the weighting method described by Huebinger et al.
utilizes an adjusted odds ratio based on previously performed
GWAS studies (Huebinger et al., 2010). This type of GWAS
data may not be available for rare diseases. To address this issue,
we have proposed a method that will weigh the PGL risk score
of each SNP using pathogenicity scores that are available from
various bioinformatics sources as an attempt to investigate a
direct impact of each SNP on the functionality of the pathway of
interest.
MOVING FORWARD
To test the method described above, we plan on analyzing
whole exome sequence data from patients exposed to moderate
(15–25mg/dL) and high (>25mg/dL) peak TSB levels at birth.
We acknowledge that it would be preferable to also investigate
the free unbound bilirubin levels for these patients, but those
data are rarely available. Because of the rarity of kernicterus
in developed countries, 1.15:100,000 live births in an average
of three studies from Denmark (Ebbesen, 2000; Ebbesen et al.,
2005; Bjerre et al., 2008) and 0.93:100,000 live births in the
United Kingdom and Ireland (Manning et al., 2007), it will likely
be necessary to obtain biological samples from international
locations such as Africa and southeast Asia where kernicterus,
unfortunately, continues to be a significant problem. The
inclusion of such disparate populations has the potential to add
additional complicating factors, including differences in genetic
background and differences in common treatment methods. We
will address these issues by comparing patients of similar ethnic
backgrounds whenever possible. The collection of biological
material for this project has received institutional review board
approval and is ongoing. Collaborating with other laboratories
internationally is also in progress.
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FIGURE 2 | Proposed pathway genetic load risk score workflow for bilirubin encephalopathy. The chevrons at each step include a description of the
proposed alterations to be made to the original workflow presented in Figure 1. Significant changes were made at the gene set creation, SNP selection and the
weighting steps. The analysis steps are largely unchanged. Abbreviations: SNP, Single Nucleotide Polymorphism; PGL, Pathway Genetic Load; aOR, adjusted odds
ratio gathered from a relevant GWAS study; SIFT, Sorting Intolerant From Tolerant score; CADD, Combined Annotation Dependent Deletion; TSB, Total Serum Bilirubin.
SUMMARY
We present a method for addressing the problems associated
with identifying the genetic factors that influence both level
of bilirubin and susceptibility to bilirubin encephalopathy
(kernicterus). Because rare diseases by definition affect small
numbers of people, it is impractical to use unbiased population-
based GWAS studies. In this paper, we present an evidence-
based candidate pathway approach in the form of the PGL
risk score that will reduce the number of genes and variants
investigated and thus reduce the need for overly large sample
sizes. We propose new alternatives for selecting pathways
and variants through the creation of custom gene lists and
use of functional scoring methods. The logistic regression
analysis proposed in Huebinger et al. will be used to determine
whether the PGL score for patients with moderate and high
TSB levels could successfully predict auditory or motor deficit
outcomes. As this method is tested and refined, we believe it
will lead to the creation of new hypotheses that will aid the
investigation of the molecular mechanisms of bilirubin toxicity
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in newborns. This work could also potentially be used to
develop a screening process for jaundiced infants that could
inform physicians about whether more aggressive treatment
is needed in infants with moderate TSB levels. Finally, this
method could be adapted to other rare or complex diseases to
address the challenge of missing heritability that exists despite
GWAS.
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